key: cord-0721402-89f2v2kx authors: Baena Espinar, J.; Torri, V.; Whisenant, J.; Hirsch, F. R.; Rogado, J.; de Castro Carpeño, J.; Halmos, B.; Ceresoli, G. L.; Rueda, A. Gomez; Tiseo, M.; Felip, E.; Tarruella, M. Majem; Monnet, I.; Tapan, U.; Wakelee, H.; Huang, L-C.; Garassino, M. C.; Peters, S.; Horn, L.; Hellmann, M. title: Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion) date: 2020-09-30 journal: Annals of Oncology DOI: 10.1016/j.annonc.2020.08.2316 sha: 33e7ecccb4a4cb1b679951bc19b66736e37d8862 doc_id: 721402 cord_uid: 89f2v2kx nan Methods: TERAVOLT is a global consortium examining outcomes and assessing risk factors associated with mortality of patients with thoracic malignancies and COVID-19 infection. Results: As of July 15, 2020, 1012 patients from 20 countries have been entered; median age was 68 with 58 % male, 80% current/former smokers, most common comorbidities of HTN (49%) & COPD (26%); 82% NSCLC, 68 % patients with stage IV disease at COVID diagnosis, 65% on treatment (38% chemotherapy, 26% immune checkpoint inhibitor (ICI), 16 % targeted tyrosine kinase inhibitor (TKI). Of these, 72% were hospitalized; 56% of patients developed complications, most frequently pneumonia (40%) and 47% who did not have prior oxygen therapy required it. 32% of patients died during their COVID-19 infection. Only 33 % of patients continued their oncology treatment after infection. Patients presenting with pneumonia (OR 2.7 2-3.5), consolidation (OR 2 CI 1,5-2,8), bilateral lung abnormalities (OR 2, 9) and pleural effusion (OR 2, 7 CI 1, were at increased risk of mortality. In multivariate analysis age 65 (OR 1,53 CI 1,11-2,1), active smoking (OR 2 CI 1,3-3), higher stage of cancer (OR 1,9 CI 1,3-2,7), ECOG PS 2 (OR 3, 7 CI 2, , steroids prior to COVID diagnosis (OR 1, 8 CI 1, 7) , were associated with increased risk of death, while chemotherapy and TKI therapy use were not and interestingly patients on immunotherapy appeared to be at decreased risk for mortality (OR 0,6 CI 0,5-0,97). Conclusions: Facing this ongoing global pandemic, TERAVOLT is the largest thoracic malignancy database confirming the high risk for COVID-19 mortality in this specific patient group. Physicians need to evaluate the risk of mortality from COVID-19 based on age, smoking status, stage of cancer, performance status, need for steroids and specific therapy in order to determine the appropriateness for cancer therapy and tailor patient care taking into account patients' wishes and status of pandemic in the country. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: BMS; Advisory/Consultancy: Merck; Advisory/Consultancy: Daiichi; Advisory/Consultancy: Genentech/Roche; Advisory/Consultancy: Lilly/Loxo Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): AstraZeneca Research grant/Funding (institution): Boehringer Ingelheim Advisory role or Speaker's bureau: AbbVie; Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: AstraZeneca Advisory role or speaker's bureau: Boehringer Ingelheim Expert testimony, Advisory role or Speaker's bureau Expert testimony, Advisory role or Speaker's bureau: Guardant Health Expert testimony, Advisory role or Speaker's bureau: Merck KGaA Expert testimony, Advisory role or Speaker's bureau: Merck Sharp and Dohme Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: prIME Oncology Expert testimony, Advisory role or Speaker's bureau: Roche Expert testimony, Advisory role or Speaker's bureau: Samsung Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau Expert testimony, Advisory role or Speaker's bureau: Takeda Research Funding: Fundacion Merck Salud; Research grant/Funding (institution), Research Funding: Grant for Oncology Innovation Full/Part-time employment, Board (Independent Member: Grifols Boards. H.A. Wakelee: Research grant/Funding (institution) Advisory/ Consultancy, advisor or consultant honoraria: AstraZeneca Research grant/Funding (institution), advisor or consultant advisor or consultant: Daiichi Sankyo, INC; Advisory/Consultancy, advisor or consultant: Helsinn; Advisory/Consultancy, advisor or consultant: Mirati Advisory/Consultancy, advisor or consultant (not: Takeda Advisory/ Consultancy, advisor or consultant (not: Cellworks Research grant/Funding (institution), advisor or consultant (not Research grant/ Funding (institution), advisor or consultant (not: Merck Travel/Accommodation/Expenses, CME presentation (travel funding): Clinical care options oncology, LLC; Travel/Accommodation/Expenses, CME presentation (travel funding): Fishawack facilitate LTD Travel/Accommodation/Expenses, CME presentation (travel funding Travel/Accommodation/Expenses, CME presentation (travel funding): Onclive/intellisphere LLC Travel/Accommodation/Expenses, CME presentation (travel funding Physician education resource, LLC/MJH; Travel/Accommodation/Expenses, CME presentation (travel funding): Potomac center for medical education; Travel/Accommodation/Expenses Travel/Accommodation/ Expenses, CME presentation (travel funding Travel/Accommodation/Expenses, CME presentation (travel funding): Research to practice Travel/Accommodation/Expenses, CME presentation (travel funding): UpToDate Travel/Accommodation/Expenses, CME presentation (travel funding Research grant/Funding (institution), honoraria, research funding to: Novartis Travel/Accommodation/Expenses, International professional society: RGCON-Rajiv gand conference Travel/Accommodation/Expenses, International professional society: JLCSjapanese lung cancer society Travel/Accommodation/Expenses, International professional society: KSMO -korean society of medical oncology Full/Part-time employment, professor of medicine: Stanford university Travel/Accommodation/Expenses, Scientific advisory committe -travel: ITMIG Research grant/Funding (institution), research funding to institution: ACEA biosciences. M.C. Garassino: Honoraria (self) Honoraria (self), Local PI, Enrollment in clinical Trials in: Otsuka Pharma Research grant/Funding (institution), PI, Enrollment and Steering: AstraZeneca; Honoraria (self) Research grant/Funding (institution), PI, Enrollment in clinical Trials in: Celgene; Research grant/Funding (institution): Incyte; Research grant/Funding (institution): Inivata PI, Enrollment in clinical Trials Thimic: Tiziana Sciences; Honoraria (self), PI, Enrollment in clinical Trials in: Clovis; Honoraria (self), PI, Enrollment in clinical Trials in Research grant/Funding (self), PI, Enrollment in clinical Trials Research grant/Funding (institution), PI, Enrollment in clinical Trials in: MSD; Honoraria (self), Local PI, Enrollment and Steering: Glax-oSmithKline S.p.A.; Research grant/Funding (institution): Sanofi-Aventis; Honoraria (self) PI, Enrollment in clinical Trials: Blueprint Medicine; Research grant/Funding (institution): Seattle Genetics; Research grant/ Funding (institution): Daiichi Sankyo Advisory/Consultancy, Advisory board + honorarium: AbbVie; Honoraria (self), Advisory/Consultancy, Advisory board + honorarium: Amgen; Honoraria (self) Advisory/Consultancy, Advisory board + honorarium: Bayer; Honoraria (self), Advisory/Consultancy, Advisory board + honorarium: Biocartis; Honoraria (self) Advisory/Consultancy, Advisory board + honorarium: Clovis; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Daiichi Sankyo; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Debiopharm; Honoraria (self), Advisory/Consultancy Advisory/Consultancy, Advisory Board + honorarium: F. Hoffmann-La Roche; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Foundation Medicine; Honoraria (self), Advisory/Consultancy Advisory/Consultancy, Advisory Board + honorarium Advisory/Consultancy, Advisory Board + honorarium: Merck Sharp and Dohme Advisory/ Consultancy, Advisory Board + honorarium: Novartis; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Pharma Mar; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Pfizer; Honoraria (self) Advisory/Consultancy, Advisory Board + honorarium: Sanofi; Honoraria (self), Advisory/Consultancy, Advisory Board + honorarium: Seattle Genetics and Takeda; Honoraria (self), Speaker Bureau/Expert testimony, Talk + honorarium: AstraZeneca; Honoraria (self Speaker Bureau/Expert testimony, Talk + honorarium Speaker Bureau/Expert testimony, Talk + honorarium: Eli Lilly; Honoraria (self), Speaker Bureau/Expert testimony, Talk + honorarium Speaker Bureau/Expert testimony, Talk + honorarium: Merck Sharp and Dohme. L. Horn: Advisory/Consultancy Consulting: Incyte Consulting: Merck Consulting: Pfizer; Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses, Consulting and travel to meeting: Xcovery; Advisory/Consultancy, Consulting: EMD Serono Consulting: AbbVie; Research grant/Funding (self): Boehringer Ingelheim Honorarium: PER; Honoraria (self), Honorarium: Research to Practice Honorarium: OncLive; Advisory/Consultancy, Consulting: Amgen; Advisory/Consultancy, Consulting: Bayer. All other authors have declared no conflicts of interest LBA76 e PR Expected medium and long term impact of the COVID-19 outbreak in oncology Legal entity responsible for the study: The authors.